WEST Search History

DATE: Monday, September 16, 2002

Set Name side by side	Query	Hit Count	Set Name result set
	DB=USPT; PLUR=YES; OP=AND		
L1	(chimera or chimeric or fusion or hybrid or recombinant).clm.	25645	L1
L2	L1 and (malar$ or plasmod$ or falciparum).clm.	76	L2
L3	L2 and holder.in.	2	L3

END OF SEARCH HISTORY

WEST

Generate Collection | Print

Search Results - Record(s) 1 through 2 of 2 returned.

☐ 1. Document ID: US 5720959 A

L3: Entry 1 of 2 File: USPT Feb 24, 1998

DOCUMENT-IDENTIFIER: US 5720959 A
TITLE: Malaria vaccine

INVENTOR (1):
Holder; Anthony A.

CLAIMS:

1. An isolated polypeptide comprising a sequence as shown in either of FIGS. 1(a) (SEQ. ID NO:1) or 1(b) (SEQ. ID NO:2) or the corresponding portion of MSP1 from a strain of Plasmodium falciparum other than Wellcome T9/94 and MAD20 in isolation from sequences naturally occurring adjacent thereto in the MSP-1 protein.

2. An isolated polypeptide comprising a sequence as shown in either of FIGS. 2(a) (SEQ. ID NO:3) or 2(b) (SEQ. ID NO:4) or the corresponding portion of MSP1 from a strain of Plasmodium falciparum other than Wellcome T9/94 and MAD20 in isolation from sequences naturally occurring adjacent thereto in the MSP-1 protein.

3. An isolated polypeptide comprising a sequence as shown in either of FIGS. 1(a) (SEQ. ID NO:1) or 1(b) (SEQ. ID NO:2) and a sequence as shown in either of FIGS. 2(a) (SEQ. ID NO:3) or 2(b) (SEQ. ID NO:4), or the corresponding portions of MSP1 from a strain of Plasmodium falciparum other than Wellcome T9/94 and MAD20 in isolation from sequences naturally occurring adjacent thereto in the MSP-1 protein.

4. An isolated nucleotide sequence encoding at least one polypeptide comprising a sequence as shown in any one of FIGS. 1(a) (SEQ. ID NO:1), 1(b) (SEQ. ID NO:2), 2(a) (SEQ. ID NO:3) or 2(b) (SEQ. ID NO:4), or the corresponding portion of MSP1 from a strain of Plasmodium falciparum other than Wellcome T9/94 and MAD20 in isolation from sequences naturally occurring adjacent thereto in the MSP-1 protein.

5. An isolated nucleotide sequence encoding a polypeptide comprising a sequence as shown in either of FIGS. 1(a) (SEQ. ID NO:1) or 1(b) (SEQ. ID NO:2) and a sequence as shown in either of FIGS. 2(a) (SEQ. ID NO:3) or 2(b) (SEQ. ID NO:4), or the corresponding portions of MSP1 from a strain of Plasmodium falciparum other than Wellcome T9/94 and MAD20 in isolation from sequences naturally occurring adjacent thereto in the MSP-1 protein.

7. The vector according to claim 6, which when inserted into a suitable host cell allows for the expression of a polypeptide comprising of a sequence as shown in any one of FIGS. 1(a) (SEQ. ID NO:1), 1(b) (SEQ. ID NO:2), 2(a) (SEQ. ID NO:3) or 2(b) (SEQ. ID NO:4), or the corresponding portion of MSP1 from another strain of Plasmodium falciparum in isolation from sequences naturally occurring adjacent thereto in the MSP-1 protein.

8. The vector according to claim 7, wherein said polypeptide is expressed as a fusion protein.

9. The vector according to claim 8, wherein said fusion protein comprises a moiety which facilitates the purification of the expressed polypeptide.

10. The vector according to claim 8, wherein said fusion protein is such that said polypeptide may be cleaved from the rest of the protein.

12. The vector according to claim 11, which when inserted into a suitable host cell allows for the expression of a polypeptide comprising a sequence as shown in any one of FIGS. 1(a) (SEQ. ID NO:1) or 1(b) (SEQ. ID NO:2), and a sequence as shown in any one of FIGS. 2(a) (SEQ. ID NO:3) or 2(b) (SEQ. ID NO:4), or the corresponding portions of MSP1 from a strain of Plasmodium falciparum other than Wellcome T9/94 and MAD20 in isolation from sequences naturally occurring adjacent thereto in the MSP-1 protein.

13. The vector according to claim 12, wherein the polypeptide is expressed as a fusion protein.

14. The vector according to claim 13, wherein said fusion protein comprises a moiety which facilitates purification of the expressed polypeptide.

15. The vector according to claim 13, wherein said fusion protein is such that said polypeptide may be cleaved from the rest of the protein.

16. A method of making a polypeptide comprising a sequence as shown in any one of FIGS. 1(a) (SEQ. ID NO:1), 1(b) (SEQ. ID NO:2), 2(a) (SEQ. ID NO:3) or 2(b) (SEQ. ID NO:4) or the corresponding portion of MSP1 from a strain of Plasmodium falciparum other than Wellcome T9/94 and MAD20 in isolation from sequences naturally occurring adjacent thereto in the MSP-1 protein, said method comprising the steps of introducing the vector of any one of claims 6-15 into a suitable host cell; growing said host cell; and isolating the polypeptide so produced.

18. A vaccine suitable for use in the prevention and/or treatment of malaria due to Plasmodium falciparum, said vaccine consisting essentially of at least one polypeptide comprising a sequence as shown in any one of FIGS. 1(a) (SEQ. ID NO:1), 1(b) (SEQ. ID NO:2), 2(a) (SEQ. ID NO:3) or 2(b) (SEQ. ID NO:4) or the corresponding portion of MSP1 from strain of Plasmodium falciparum other than Wellcome T9/94 and MAD20 in isolation from sequences naturally occurring adjacent thereto in the MSP-1 protein, said vaccine further comprising a physiologically acceptable carrier.

19. A vaccine suitable for use in the prevention and/or treatment of malaria due to Plasmodium falciparum, said vaccine comprising a polypeptide consisting essentially of a sequence as shown in any one of FIGS. 1(a) (SEQ. ID NO:1) or 1(b) (SEQ. ID NO:2) and a sequence as shown in any one of FIGS. 2(a) (SEQ. ID NO:3) or 2(b) (SEQ. ID NO:4) or the corresponding portion of MSP1 from a strain of Plasmodium falciparum other than Wellcome T9/94 and MAD20 in isolation from sequences naturally occurring adjacent thereto in the MSP-1 protein, said vaccine further comprising a physiologically acceptable carrier.

20. The vaccine according to claim 18 or 19, wherein said polypeptide is present as a fusion protein.

21. A method of preventing and/or treating a human body for malaria due to Plasmodium falciparum, comprising administering an effective amount of a vaccine according to claim 18 or 19.

☐ 2. Document ID: US 5597708 A

L3: Entry 2 of 2 File: USPT Jan 28, 1997

DOCUMENT-IDENTIFIER: US 5597708 A
TITLE: Cloning of a malarial gene

INVENTOR (1):
Holder; Anthony A.

CLAIMS:

1. An isolated nucleic acid consisting of a sequence encoding the P.195 protein of P. falciparum having the amino acid sequence shown in FIGS. 1A-1I.

12. A recombinant molecule comprising a vector and a nucleic acid sequence selected from the group consisting of the isolated nucleic acids of claims 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, and 11.

13. The recombinant molecule according to claim 12, further comprising a control sequence that is operably linked to said nucleic acid sequence and regulates the expression of said nucleic acid sequence.

14. The recombinant molecule according to claim 13, further comprising a heterologous protein coding sequence tandemly linked amino terminal to said DNA sequence.

15. A host cell comprising the recombinant molecule according to claim 12.

Generate Collection Print

Terms	Documents
L2 and holder.in.	2

Display Format: KWIC Change Format

Previous Page Next Page